Amgen


Amgen Wins FDA Approval for Breakthrough Lung Cancer Drug

The FDA has given Amgen (AMGN) the green light to bring its breakthrough lung cancer drug Lumakras to the market. Amgen is a …

Amgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79%

Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology …

Amgen’s Experimental Lung Cancer Drug Gets Approval In China

Amgen announced on Jan. 29 that its experimental lung cancer drug, sotorasib, had been granted “Breakthrough Therapy Designation (BTD)” by the Center for …

Amgen, AstraZeneca Deliver Positive Results For Late-Stage Severe Asthma Trial

Amgen (AMGN) and AstraZeneca (AZN) have announced positive topline results from the Phase 3 Navigator trial for tezepelumab, which demonstrated a statistically significant …

Amgen’s 3Q Top Line Gains 12% Fueled By Strong Drug Sales

Amgen Inc.’ 3Q revenues jumped 12% to $6.

Amgen Pours A Further $421M Into China’s BeiGene

Amgen (AMGN) has announced an additional investment of approximately $421 million in BeiGene’s (BGNE) registered direct offering of ordinary shares. This investment maintains Amgen’s current …

Stock Update (NASDAQ:AMGN): Here’s Why Amgen, Inc. Shares Are Falling 10% Today

Amgen, Inc. (NASDAQ:AMGN) shares are falling nearly 10% in Friday’s trading session, leaving investors scratching their heads after the biotech giant actually reported above consensus third-quarter revenues …

Biotech Beat: Amgen, Inc. (AMGN) and Gilead Sciences, Inc. (GILD) News

There are many things that cause a stock to move: acquisition rumors, news stories (both positive and negative), earnings releases, analyst upgrades/downgrades, ETF-forced …

Cracking The Best Healthcare Dividend Stock Secret

This Weekend my eyes and thoughts curved around the Healthcare sector.  I read several interesting articles from the sector, mostly about the biotech’s …

Amgen: A Dividend Growing Powerhouse In My Portfolio

The stock market isn’t providing good discounts especially in quality names, but at least the return of volatility is providing some opportunities for …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts